Dextroamphetamine

Generic Name: Dextroamphetamine

Brand Names: Adderall, Dexedrine, Mydayis, Procentra, Xelstrym, Zenzedi

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N

CAS Number: 51-64-9

Unique Ingredient Identifier: TZ47U051FI

Background: Dextroamphetamine is the dextrorotary enantiomer of amphetamine. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.

Indication: Dextroamphetamine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).

Associated Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Narcolepsy

Associated Therapies: -

Clinical Trials

MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder

Phase 2

Not yet recruiting

Conditions: Post Traumatic Stress Disorder

Interventions: Drug: d-amphetamine
Drug: 3,4-methylenedioxymethamphetamine
Behavioral: Therapy

First Posted Date: 2023-03-30

Last Posted Date: 2023-03-30

Lead Sponsor: Stephen Robert Marder

Target Recruit Count: 40

Registration Number: NCT05790239

Locations: 🇺🇸
VA Greater Los Angeles Healthcare System, Westwood campus, Los Angeles, California, United States

The Difference in the Mechanism of Action Between Two Brands of Dexamfetamine in Adults With ADHD

Not Applicable

Recruiting

Conditions: Attention Deficit Disorder With Hyperactivity

Interventions: Drug: Dexamfetamine

First Posted Date: 2022-11-17

Last Posted Date: 2023-10-12

Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Target Recruit Count: 26

Registration Number: NCT05621174

Locations: 🇳🇱
Glenn Dumont, Amsterdam, Noord-Holland, Netherlands

[C-11]NPA PET-amphetamine in Cocaine Use Disorders

Early Phase 1

Recruiting

Conditions: Cocaine Use Disorder

Interventions: Radiation: Baseline [C-11]NPA PET Scan
Drug: d-amphetamine
Radiation: Post-amphetamine [C-11]NPA PET Scan

First Posted Date: 2021-08-18

Last Posted Date: 2024-12-13

Lead Sponsor: Rajesh Narendran

Target Recruit Count: 30

Registration Number: NCT05011760

Locations: 🇺🇸
University of PIttsburgh, PIttsburgh, Pennsylvania, United States

Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Drug: Placebo
Drug: d-amphetamine

First Posted Date: 2020-06-04

Last Posted Date: 2024-11-05

Lead Sponsor: University of California, San Diego

Target Recruit Count: 28

Registration Number: NCT04414930

Locations: 🇺🇸
Clinical Teaching Facility (CTF-B102) at UCSD Medical Center, San Diego, California, United States

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

Completed

Conditions: Attention Deficit Disorder With Hyperactivity

Interventions: Drug: Lisdexamfetamine
Drug: Amphetamine
Drug: Methylphenidate
Drug: Atomoxetine
Drug: Dextroamphetamine

First Posted Date: 2019-10-21

Last Posted Date: 2019-11-08

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 430000

Registration Number: NCT04132557

Locations: 🇺🇸
Janssen Investigative Site, Titusville, New Jersey, United States

Imaging Dopamine D2 Agonist Binding Sites in Schizophrenia

Withdrawn

Conditions: Schizophrenia

Interventions: Drug: NPA radiotracer
Drug: Raclopride radiotracer
Drug: Dextroamphetamine

First Posted Date: 2019-06-26

Last Posted Date: 2020-05-29

Lead Sponsor: NYU Langone Health

Registration Number: NCT03999190

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

Brain Mechanisms in Young Adults

Early Phase 1

Completed

Conditions: Cocaine-Related Disorders

Interventions: Drug: d-amphetamine
Radiation: [C-11]NPA

First Posted Date: 2018-07-30

Last Posted Date: 2020-09-03

Lead Sponsor: Gale Richardson

Target Recruit Count: 13

Registration Number: NCT03606473

Locations: 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Decision Making Study in Young and Middle-Aged Adults: Part II

Phase 1

Completed

Conditions: Healthy Adults

Interventions: Diagnostic Test: [18F]-FE-PE2I
Drug: Placebo
Drug: Dextroamphetamine
Diagnostic Test: [18F]Fallypride

First Posted Date: 2018-04-30

Last Posted Date: 2019-06-27

Lead Sponsor: Vanderbilt University

Target Recruit Count: 65

Registration Number: NCT03512171

Locations: 🇺🇸
Zald Affective Neuroscience Lab- Vanderbilt University, Nashville, Tennessee, United States

Bariatric Surgery and Pharmacokinetics of Dexamphetamine

Completed

Conditions: Obesity, Morbid

First Posted Date: 2018-03-09

Last Posted Date: 2024-10-07

Lead Sponsor: Norwegian University of Science and Technology

Target Recruit Count: 12

Registration Number: NCT03460353

Locations: 🇳🇴
St. Olavs University Hospital, Trondheim, Norway

Cocaine Use Disorder and Cortical Dopamine

Early Phase 1

Completed

Conditions: Cocaine Dependence

Interventions: Drug: d-amphetamine
Radiation: [C-11]FLB 457

First Posted Date: 2017-11-21

Last Posted Date: 2020-06-04

Lead Sponsor: University of Pittsburgh

Target Recruit Count: 30

Registration Number: NCT03349606

Locations: 🇺🇸
University of PIttsburgh PET Facility, Pittsburgh, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy